Introduction to special issue on protected areas

J. Mcneely

DOI: https://doi.org/10.1007/BF00057796

IF: 3.4

Biodiversity and Conservation

Abstract:

What problem does this paper attempt to address?

Targeting Hemagglutinin: Approaches for Broad Protection against the Influenza A Virus

Yun Zhang,Cong Xu,Hao Zhang,George Dacai Liu,Chunyi Xue,Yongchang Cao

DOI: https://doi.org/10.3390/v11050405

2019-04-30

Viruses

Abstract:Influenza A viruses are dynamically epidemic and genetically diverse. Due to the antigenic drift and shift of the virus, seasonal vaccines are required to be reformulated annually to match with current circulating strains. However, the mismatch between vaccinal strains and circulating strains occurs frequently, resulting in the low efficacy of seasonal vaccines. Therefore, several "universal" vaccine candidates based on the structure and function of the hemagglutinin (HA) protein have been developed to meet the requirement of a broad protection against homo-/heterosubtypic challenges. Here, we review recent novel constructs and discuss several important findings regarding the broad protective efficacy of HA-based universal vaccines.
Targeting Antigens for Universal Influenza Vaccine Development

Quyen-Thi Nguyen,Young-Ki Choi

DOI: https://doi.org/10.3390/v13060973

2021-05-24

Viruses

Abstract:Traditional influenza vaccines generate strain-specific antibodies which cannot provide protection against divergent influenza virus strains. Further, due to frequent antigenic shifts and drift of influenza viruses, annual reformulation and revaccination are required in order to match circulating strains. Thus, the development of a universal influenza vaccine (UIV) is critical for long-term protection against all seasonal influenza virus strains, as well as to provide protection against a potential pandemic virus. One of the most important strategies in the development of UIVs is the selection of optimal targeting antigens to generate broadly cross-reactive neutralizing antibodies or cross-reactive T cell responses against divergent influenza virus strains. However, each type of target antigen for UIVs has advantages and limitations for the generation of sufficient immune responses against divergent influenza viruses. Herein, we review current strategies and perspectives regarding the use of antigens, including hemagglutinin, neuraminidase, matrix proteins, and internal proteins, for universal influenza vaccine development.
A general solution to broad-spectrum vaccine design for rapidly mutating viruses

Jacob Glanville,Sarah Ives,Jean-Philippe Bürckert,Christina Pettus,Karina Reyna Peñate,Rachel Hovde,Nicholas Bayless,Devanshi Shanghavi,Keith Glanville,Erwin Calgua,Sawsan Youssef

DOI: https://doi.org/10.21203/rs.3.rs-100459/v1

2020-12-29

Abstract:Abstract Rapidly evolving pathogens pose a challenge to vaccine design, as their mutations render previous vaccine responses obsolete. For influenza, conserved epitopes on the viral coat proteins have been identified, but mysteriously they are missed by the antibodies elicited by most vaccine recipients [1, 2]. In simulated immunizations using 263 million antibody-hemagglutinin (HA) structural docking solutions, non-conserved epitopes were immunodominant when HAs were immunized at standard concentrations. However, by vaccinating with a pool of 30 diverse and dilute HA variants, B-cells that recognize broadly-conserved epitopes across HA receive up to 30-fold higher antigen dose, with concentration being linearly correlated to conservation on a per epitope basis. If individual variants are at concentrations below the minimum threshold of immune activation, then cross-reactive B-cells will be preferentially elicited. In pig immunizations, the approach induced a broad-spectrum antibody response against a panel of 36 strains from 1918-2014, including all pandemic strains from the past century and multiple strains not in the vaccine. In further swine studies with a vaccine containing HAs from 1918-2008, we observe broad-spectrum neutralizing responses against 6 future heterologous strains, including pandemic strains, spanning H1N1 2009-2017 and H3N2 2009-2014. Our results support a greater understanding of why non-conserved epitopes are immunodominant, as well as indicate a general solution to overcome this in broad-spectrum vaccine design.
Generation and Characterization of Monoclonal Antibodies Against the Hemagglutinin of H3N2 Influenza A Viruses.

Fan Yang,Linwei Zhu,Fumin Liu,Linfang Cheng,Hangping Yao,Nanping Wu,Haibo Wu,Lanjuan Li

DOI: https://doi.org/10.1016/j.virusres.2022.198815

IF: 6.286

2022-01-01

Virus Research

Abstract:Seasonal influenza viruses are highly contagious, leading to 290,000-650,000 mortalities every year globally. Among the influenza viruses, influenza A virus (H3N2) has attracted much attention due to its high frequency of antigenic variations, resulting in poor protection by vaccination. We generated a panel of murine neutralizing monoclonal antibodies (mAbs) against A/Texas/50/2012 (H3N2) and identified the relevant epitopes that potentially influence the antigenicity by selecting mAb-resistant mutants. The epitopes were mainly in antigenic site A (1/9, 11.1%), B (6/9, 66.7%), and C (1/9, 11.1%), which is consistent with recent reports on the immunodominance of antigenic site B. The amino acid substitutions at positions 156, 157, 159, 160, and 189 at antigenic site B resulted in decreased mAb capability for blocking receptor binding. In addition, the neutralizing spectra of three mAbs (1F8, 1G9 and 1H5) were different, suggesting that their epitopes may be different but partially overlapping, and it required further study. Further, the mAb 3F9 selected a new substitution, D53G/N, at antigenic site C and showed in vitro neutralizing activity against A/Victoria/361/2011 (H3N2), A/Texas/50/2012 (H3N2), and A/Hong Kong/2671/2019 (H3N2), suggesting a potential epitope on H3 hemagglutinin for inducing broad neutralizing antibody responses. Continuous research and regular monitoring of novel epitopes are of great importance for improving vaccine strain selection.
Towards a universal influenza vaccine: different approaches for one goal

Giuseppe A. Sautto,Greg A. Kirchenbaum,Ted M. Ross

DOI: https://doi.org/10.1186/s12985-017-0918-y

IF: 5.916

2018-01-19

Virology Journal

Abstract:Influenza virus infection is an ongoing health and economic burden causing epidemics with pandemic potential, affecting 5–30% of the global population annually, and is responsible for millions of hospitalizations and thousands of deaths each year. Annual influenza vaccination is the primary prophylactic countermeasure aimed at limiting influenza burden. However, the effectiveness of current influenza vaccines are limited because they only confer protective immunity when there is antigenic similarity between the selected vaccine strains and circulating influenza isolates. The major targets of the antibody response against influenza virus are the surface glycoprotein antigens hemagglutinin (HA) and neuraminidase (NA). Hypervariability of the amino acid sequences encoding HA and NA is largely responsible for epidemic and pandemic influenza outbreaks, and are the consequence of antigenic drift or shift, respectively. For this reason, if an antigenic mismatch exists between the current vaccine and circulating influenza isolates, vaccinated people may not be afforded complete protection. There is currently an unmet need to develop an effective “broadly-reactive” or “universal” influenza vaccine capable of conferring protection against both seasonal and newly emerging pre-pandemic strains. A number of novel influenza vaccine approaches are currently under evaluation. One approach is the elicitation of an immune response against the “Achille’s heel” of the virus, i.e. conserved viral proteins or protein regions shared amongst seasonal and pre-pandemic strains. Alternatively, other approaches aim toward eliciting a broader immune response capable of conferring protection against the diversity of currently circulating seasonal influenza strains.In this review, the most promising under-development universal vaccine approaches are discussed with an emphasis on those targeting the HA glycoprotein. In particular, their strengths and potential short-comings are discussed. Ultimately, the upcoming clinical evaluation of these universal vaccine approaches will be fundamental to determine their effectiveness against preventing influenza virus infection and/or reducing transmission and disease severity.

virology
Free-energy Simulations Reveal That Both Hydrophobic and Polar Interactions Are Important for Influenza Hemagglutinin Antibody Binding.

Zhen Xia,Tien Huynh,Seung-gu Kang,Ruhong Zhou

DOI: https://doi.org/10.1016/j.bpj.2012.01.043

IF: 3.4

2012-01-01

Biophysical Journal

Abstract:Antibodies binding to conserved epitopes can provide a broad range of neutralization to existing influenza subtypes and may also prevent the propagation of potential pandemic viruses by fighting against emerging strands. Here we propose a computational framework to study structural binding patterns and detailed molecular mechanisms of viral surface glycoprotein hemagglutinin (HA) binding with a broad spectrum of neutralizing monoclonal antibody fragments (Fab). We used rigorous free-energy perturbation (FEP) methods to calculate the antigen-antibody binding affinities, with an aggregate underlying molecular-dynamics simulation time of several microseconds (∼2 μs) using all-atom, explicit-solvent models. We achieved a high accuracy in the validation of our FEP protocol against a series of known binding affinities for this complex system, with <0.5 kcal/mol errors on average. We then introduced what to our knowledge are novel mutations into the interfacial region to further study the binding mechanism. We found that the stacking interaction between Trp-21 in HA2 and Phe-55 in the CDR-H2 of Fab is crucial to the antibody-antigen association. A single mutation of either W21A or F55A can cause a binding affinity decrease of ΔΔG > 4.0 kcal/mol (equivalent to an ∼1000-fold increase in the dissociation constant K(d)). Moreover, for group 1 HA subtypes (which include both the H1N1 swine flu and the H5N1 bird flu), the relative binding affinities change only slightly (< ±1 kcal/mol) when nonpolar residues at the αA helix of HA mutate to conservative amino acids of similar size, which explains the broad neutralization capability of antibodies such as F10 and CR6261. Finally, we found that the hydrogen-bonding network between His-38 (in HA1) and Ser-30/Gln-64 (in Fab) is important for preserving the strong binding of Fab against group 1 HAs, whereas the lack of such hydrogen bonds with Asn-38 in most group 2 HAs may be responsible for the escape of antibody neutralization. These large-scale simulations may provide new insight into the antigen-antibody binding mechanism at the atomic level, which could be essential for designing more-effective vaccines for influenza.
Recent Advances, Approaches and Challenges in the Development of Universal Influenza Vaccines

Caryn Myn Li Lim,Thamil Vaani Komarasamy,Nur Amelia Azreen Binti Adnan,Ammu Kutty Radhakrishnan,Vinod R. M. T. Balasubramaniam

DOI: https://doi.org/10.1111/irv.13276

2024-03-22

Influenza and Other Respiratory Viruses

Abstract:Every year, influenza virus infections cause significant morbidity and mortality worldwide. They pose a substantial burden of disease, in terms of not only health but also the economy. Owing to the ability of influenza viruses to continuously evolve, annual seasonal influenza vaccines are necessary as a prophylaxis. However, current influenza vaccines against seasonal strains have limited effectiveness and require yearly reformulation due to the virus undergoing antigenic drift or shift. Vaccine mismatches are common, conferring suboptimal protection against seasonal outbreaks, and the threat of the next pandemic continues to loom. Therefore, there is a great need to develop a universal influenza vaccine (UIV) capable of providing broad and durable protection against all influenza virus strains. In the quest to develop a UIV that would obviate the need for annual vaccination and formulation, a multitude of strategies is currently underway. Promising approaches include targeting the highly conserved epitopes of haemagglutinin (HA), neuraminidase (NA), M2 extracellular domain (M2e) and internal proteins of the influenza virus. The identification and characterization of broadly neutralizing antibodies (bnAbs) targeting conserved regions of the viral HA protein, in particular, have provided important insight into novel vaccine designs and platforms. This review discusses universal vaccine approaches presently under development, with an emphasis on those targeting the highly conserved stalk of the HA protein, recent technological advancements used and the future prospects of a UIV in terms of its advantages, developmental obstacles and potential shortcomings.

infectious diseases,virology
Flu Universal Vaccines: New Tricks on an Old Virus

Ruikun Du,Qinghua Cui,Lijun Rong

DOI: https://doi.org/10.1007/s12250-020-00283-6

2020-01-01

Abstract:Conventional influenza vaccines are based on predicting the circulating viruses year by year, conferring limited effectiveness since the antigenicity of vaccine strains does not always match the circulating viruses. This necessitates development of universal influenza vaccines that provide broader and lasting protection against pan-influenza viruses. The discovery of the highly conserved immunogens (epitopes) of influenza viruses provides attractive targets for universal vaccine design. Here we review the current understanding with broadly protective immunogens (epitopes) and discuss several important considerations to achieve the goal of universal influenza vaccines.
Structural and immunological characterization of the H3 influenza hemagglutinin during antigenic drift

Rebeca de Paiva Froes Rocha,Ilhan Tomris,Charles A. Bowman,Emma Stevens,Jason Kantorow,Weiwei Peng,Svearike Oeverdieck,James A. Ferguson,Diana D. Jung,Sander Herfst,Joost Snijder,Srirupa Chakraborty,Alba Torrents de la Peña,Zachary T. Berndsen,Robert P. de Vries,Andrew B. Ward

DOI: https://doi.org/10.1101/2024.09.13.612776

2024-09-19

Abstract:The quest for a universal influenza vaccine holds great promise for mitigating the global burden of influenza-related morbidity and mortality. However, challenges persist in identifying conserved epitopes capable of inducing protection. In this study, we explore the influence of glycan evolution on H3 hemagglutinin from 1968 to present day and its impacts on antigenicity and immunogenicity. We observe that the appearance of potential N-linked glycosylation sites in Sing/16 hemagglutinin head domain reduces the binding of broadly neutralizing antibodies and shifts the polyclonal immune response upon vaccination to target the stem. Furthermore, structural characterization of HK/68 and Sing/16 by cryo-electron microscopy shows that while HK/68 is resistant to enzymatic deglycosylation, removal of glycans destabilizes the hyperglycosylated head and membrane-proximal region in Sing/16. These insights expand our understanding of glycans beyond their role in protein folding and highlight the interplay among glycan integration and immune recognition to design a universal influenza vaccine.

Immunology
Influenza Hemagglutinin and Neuraminidase: Yin–Yang Proteins Coevolving to Thwart Immunity

Ivan Kosik,Jonathan W Yewdell,Jonathan W. Yewdell

DOI: https://doi.org/10.3390/v11040346

2019-04-16

Viruses

Abstract:Influenza A virions possess two surface glycoproteins—the hemagglutinin (HA) and neuraminidase (NA)—which exert opposite functions. HA attaches virions to cells by binding to terminal sialic acid residues on glycoproteins/glycolipids to initiate the infectious cycle, while NA cleaves terminal sialic acids, releasing virions to complete the infectious cycle. Antibodies specific for HA or NA can protect experimental animals from IAV pathogenesis and drive antigenic variation in their target epitopes that impairs vaccine effectiveness in humans. Here, we review progress in understanding HA/NA co-evolution as each acquires epistatic mutations to restore viral fitness to mutants selected in the other protein by host innate or adaptive immune pressure. We also discuss recent exciting findings that antibodies to HA can function in vivo by blocking NA enzyme activity to prevent nascent virion release and enhance Fc receptor-based activation of innate immune cells.
Targeting neuraminidase: the next frontier for broadly protective influenza vaccines

Nicholas C Wu,Ali H Ellebedy,Nicholas C. Wu,Ali H. Ellebedy

DOI: https://doi.org/10.1016/j.it.2023.11.001

IF: 19.709

2024-01-12

Trends in Immunology

Abstract:Current seasonal influenza vaccines, which mainly target hemagglutinin (HA), require annual updates due to the continuous antigenic drift of the influenza virus. Developing an influenza vaccine with increased breadth of protection will have significant public health benefits. The recent discovery of broadly protective antibodies to neuraminidase (NA) has provided important insights into developing a universal influenza vaccine, either by improving seasonal influenza vaccines or designing novel immunogens. However, further in-depth molecular characterizations of NA antibody responses are warranted to fully leverage broadly protective NA antibodies for influenza vaccine designs. Overall, we posit that focusing on NA for influenza vaccine development is synergistic with existing efforts targeting HA, and may represent a cost-effective approach to generating a broadly protective influenza vaccine.

immunology
[In search of the individual degree of resection in gastrointestinal disease?].

J. Siewert

Abstract:
Proteolytic processing of the plum pox potyvirus polyprotein by the NIa protease at a novel cleavage site.

J. García,M. T. Martín,M. Cervera,J. Riechmann

DOI: https://doi.org/10.1016/0042-6822(92)90524-S

IF: 3.513

1992-06-01

Virology

Abstract:
Age-dependent heterogeneity in the antigenic effects of mutations to influenza hemagglutinin

Frances C Welsh,Rachel T Eguia,Juhye M Lee,Hugh K Haddox,Jared Galloway,Nguyen Van Vinh Chau,Andrea N Loes,John Huddleston,Timothy C Yu,Mai Quynh Le,Nguyen T D Nhat,Nguyen Thi Le Thanh,Alexander L Greninger,Helen Y Chu,Janet A Englund,Trevor Bedford,Frederick A Matsen 4th,Maciej F Boni,Jesse D Bloom

DOI: https://doi.org/10.1016/j.chom.2024.06.015

2024-08-14

Abstract:Human influenza virus evolves to escape neutralization by polyclonal antibodies. However, we have a limited understanding of how the antigenic effects of viral mutations vary across the human population and how this heterogeneity affects virus evolution. Here, we use deep mutational scanning to map how mutations to the hemagglutinin (HA) proteins of two H3N2 strains, A/Hong Kong/45/2019 and A/Perth/16/2009, affect neutralization by serum from individuals of a variety of ages. The effects of HA mutations on serum neutralization differ across age groups in ways that can be partially rationalized in terms of exposure histories. Mutations that were fixed in influenza variants after 2020 cause greater escape from sera from younger individuals compared with adults. Overall, these results demonstrate that influenza faces distinct antigenic selection regimes from different age groups and suggest approaches to understand how this heterogeneous selection shapes viral evolution.
Conserved sites on the influenza H1 and H3 hemagglutinin recognized by human antibodies

Daniel P Maurer,Mya Vu,Ana S Ferreira Ramos,Haley L Dugan,Paul Khalife,James C Geoghegan,Laura M Walker,Goran Bajic,Aaron G Schmidt

DOI: https://doi.org/10.1101/2024.10.22.619298

2024-11-02

Abstract:Monoclonal antibodies (mAbs) targeting the influenza hemagglutinin (HA) have the potential to be used as prophylactics or templates for next-generation vaccines that provide broad protection. Here, we isolated broad, subtype-neutralizing mAbs from human B cells targeting the H1 or H3 HA head as well as a unique mAb targeting the stem. The H1 mAbs target the previously defined lateral patch epitope on H1 HAs and recognize HAs from 1933 to 2021 in addition to a swine H1N1 virus with pandemic potential. Using directed evolution, we improved the neutralization potency of these H1 mAbs towards a contemporary H1 strain. Using deep mutational scanning of four antigenically distinct H1N1 viruses, we identified potential viral escape pathways. For the H3 mAbs we used cryo-EM to define the targeted epitopes: one mAb recognizes the side of the H3 head, accommodating the N133 glycan and a pocket underneath the receptor binding site. The other H3 mAb recognizes an epitope in the HA stem that overlaps with previously characterized mAbs, but with distinct antibody variable genes and mode of recognition. Collectively, these mAbs identify common sites recognized by broad, subtype-specific mAbs that may be elicited by next-generation vaccines.

Immunology
Defining influenza A virus hemagglutinin antigenic drift by sequential monoclonal antibody selection

Suman R Das,Scott E Hensley,William L Ince,Christopher B Brooke,Anju Subba,Mark G Delboy,Gustav Russ,James S Gibbs,Jack R Bennink,Jonathan W Yewdell

DOI: https://doi.org/10.1016/j.chom.2013.02.008

2013-03-13

Abstract:Human influenza A virus (IAV) vaccination is limited by "antigenic drift," rapid antibody-driven escape reflecting amino acid substitutions in the globular domain of hemagglutinin (HA), the viral attachment protein. To better understand drift, we used anti-hemagglutinin monoclonal Abs (mAbs) to sequentially select IAV escape mutants. Twelve selection steps, each resulting in a single amino acid substitution in the hemagglutinin globular domain, were required to eliminate antigenicity defined by monoclonal or polyclonal Abs. Sequential mutants grow robustly, showing the structural plasticity of HA, although several hemagglutinin substitutions required an epistatic substitution in the neuraminidase glycoprotein to maximize growth. Selecting escape mutants from parental versus sequential variants with the same mAb revealed distinct escape repertoires, attributed to contextual changes in antigenicity and the mutation landscape. Since each hemagglutinin mutation potentially sculpts future mutation space, drift can follow many stochastic paths, undermining its unpredictability and underscoring the need for drift-insensitive vaccines.
Recent advances in “universal” influenza virus antibodies: the rise of a hidden trimeric interface in hemagglutinin globular head

Yulu Wang,Dan Hu,Yanling Wu,Tianlei Ying

DOI: https://doi.org/10.1007/s11684-020-0764-y

2020-01-01

Frontiers of Medicine

Abstract:Influenza causes seasonal outbreaks yearly and unpredictable pandemics with high morbidity and mortality rates. Despite significant efforts to address influenza, it remains a major threat to human public health. This issue is partially due to the lack of antiviral drugs with potent antiviral activity and broad reactivity against all influenza virus strains and the rapid emergence of drug-resistant variants. Moreover, designing a universal influenza vaccine that is sufficiently immunogenic to induce universal antibodies is difficult. Some novel epitopes hidden in the hemagglutinin (HA) trimeric interface have been discovered recently, and a number of antibodies targeting these epitopes have been found to be capable of neutralizing a broad range of influenza isolates. These findings may have important implications for the development of universal influenza vaccines and antiviral drugs. In this review, we focused on the antibodies targeting these newly discovered epitopes in the HA domain of the influenza virus to promote the development of universal anti-influenza antibodies or vaccines and extend the discovery to other viruses with similar conformational changes in envelope proteins.
Discordant Antigenic Drift of Neuraminidase and Hemagglutinin in H1N1 and H3N2 Influenza Viruses

Matthew R. Sandbulte,Kim B. Westgeest,Jin Gao,Xinhua Xu,Alexander Klimov,Colin A. Russell,David F. Burke,Derek J. Smith,Ron A. M. Fouchier,Maryna C. Eichelberger

DOI: https://doi.org/10.1073/pnas.1113801108

2011-01-01

Abstract:Seasonal epidemics caused by influenza virus are driven by antigenic changes (drift) in viral surface glycoproteins that allow evasion from preexisting humoral immunity. Antigenic drift is a feature of not only the hemagglutinin (HA), but also of neuraminidase (NA). We have evaluated the antigenic evolution of each protein in H1N1 and H3N2 viruses used in vaccine formulations during the last 15 y by analysis of HA and NA inhibition titers and antigenic cartography. As previously shown for HA, genetic changes in NA did not always lead to an antigenic change. The noncontinuous pattern of NA drift did not correspond closely with HA drift in either subtype. Although NA drift was demonstrated using ferret sera, we show that these changes also impact recognition by NA-inhibiting antibodies in human sera. Remarkably, a single point mutation in the NA of A/Brisbane/59/2007 was primarily responsible for the lack of inhibition by polyclonal antibodies specific for earlier strains. These data underscore the importance of NA inhibition testing to define antigenic drift when there are sequence changes in NA.
Turning vaccine design on its head

Katarzyna Ciazynska

DOI: https://doi.org/10.1038/s41594-024-01234-5

2024-02-17

Nature Structural & Molecular Biology

Abstract:Different subtypes of influenza fusion protein hemagglutinin are included in the vaccine cocktail. However, the immune response is often produced against the immunodominant, variable region of hemagglutinin, while it is of interest to develop broadly neutralizing antibodies against the stem region, which is conserved. Eliciting an immune response against a conserved region promises broader protection against other strains. Immunofocusing aims to accomplish this by targeting the immune response towards conserved epitopes on the antigen. This approach is not only of interest in flu vaccine development, but also for other viral proteins, including the HIV-1 Env protein, SARS-CoV-2 spike protein and Ebola glycoprotein. Developing epitope-focused vaccines against conserved regions of viral proteins is a major part of pandemic preparedness.

cell biology,biochemistry & molecular biology,biophysics
Identification and Characterization of Novel Antibody Epitopes on the N2 Neuraminidase

Ericka Kirkpatrick Roubidoux,Meagan McMahon,Juan Manuel Carreño,Christina Capuano,Kaijun Jiang,Viviana Simon,Harm van Bakel,Patrick Wilson,Florian Krammer

DOI: https://doi.org/10.1128/mSphere.00958-20

2021-02-10

mSphere

Abstract:The influenza virus neuraminidase (NA) is becoming a focus for novel vaccine designs. However, the epitopes of human anti-NA antibodies have been poorly defined. Using a panel of 10 anti-N2 monoclonal antibodies (MAbs) that bind the H3N2 virus A/Switzerland/9715293/2013, we generated five escape mutant viruses. These viruses contained mutations K199E/T, E258K, A272D, and S331N. We found that mutations at K199 and E258 had the largest impact on MAb binding, NA inhibition and neutralization activity. In addition, a natural isolate from the 2017-2018 season was found to contain the E258K mutation and was resistant to numerous antibodies tested. The mutation S331N, was identified in virus passaged in the presence of antibody; however, it had little impact on MAb activity and greatly decreased viral fitness. This information aids in identifying novel human MAb epitopes on the N2 and helps with the detection of antigenically drifted NAs.IMPORTANCE The influenza virus neuraminidase is an emerging target for universal influenza virus vaccines. However, in contrast to influenza virus hemagglutinin, we know little about antibody epitopes and antigenic sites on the neuraminidase. Characterizing and defining these sites is aiding vaccine development and helping to understand antigenic drift of NA.

Introduction to special issue on protected areas

Targeting Hemagglutinin: Approaches for Broad Protection against the Influenza A Virus

Targeting Antigens for Universal Influenza Vaccine Development

A general solution to broad-spectrum vaccine design for rapidly mutating viruses

Generation and Characterization of Monoclonal Antibodies Against the Hemagglutinin of H3N2 Influenza A Viruses.

Towards a universal influenza vaccine: different approaches for one goal

Free-energy Simulations Reveal That Both Hydrophobic and Polar Interactions Are Important for Influenza Hemagglutinin Antibody Binding.

Recent Advances, Approaches and Challenges in the Development of Universal Influenza Vaccines

Flu Universal Vaccines: New Tricks on an Old Virus

Structural and immunological characterization of the H3 influenza hemagglutinin during antigenic drift

Influenza Hemagglutinin and Neuraminidase: Yin–Yang Proteins Coevolving to Thwart Immunity

Targeting neuraminidase: the next frontier for broadly protective influenza vaccines

[In search of the individual degree of resection in gastrointestinal disease?].

Proteolytic processing of the plum pox potyvirus polyprotein by the NIa protease at a novel cleavage site.

Age-dependent heterogeneity in the antigenic effects of mutations to influenza hemagglutinin

Conserved sites on the influenza H1 and H3 hemagglutinin recognized by human antibodies

Defining influenza A virus hemagglutinin antigenic drift by sequential monoclonal antibody selection

Recent advances in “universal” influenza virus antibodies: the rise of a hidden trimeric interface in hemagglutinin globular head

Discordant Antigenic Drift of Neuraminidase and Hemagglutinin in H1N1 and H3N2 Influenza Viruses

Turning vaccine design on its head

Identification and Characterization of Novel Antibody Epitopes on the N2 Neuraminidase